LSD Chemistry & Science

LSD Chemistry & Science: The Complete Evidence-Based Guide

Quick Summary:  LSD (lysergic acid diethylamide) is a semisynthetic ergoline alkaloid derived from Claviceps purpurea, the ergot fungus that grows on rye. Its molecular formula is C₂₀H₂₅N₃O — molecular weight 323.43 g/mol, CAS 50-37-3. First synthesized by Albert Hofmann at Sandoz Laboratories in 1938, it became the most potent psychoactive compound ever identified. This article covers the full chemistry: what LSD is made of, where it comes from, how it is synthesized, and what the lsd chemical structure reveals about its pharmacology. Two dedicated deep-dive articles follow: Chemical Structure & Formula and Origins & Synthesis.

There are two kinds of articles about LSD chemistry online. The first kind waves vaguely at ‘ergot fungus’ and moves on. The second kind is so dense with IUPAC nomenclature it serves no one except specialists who already know the material. This article is neither. It is the complete chemistry and science of the lsd molecule explained in plain, accurate language — grounded in peer-reviewed sources, real synthesis data, and the structural insights that come from a 2017 crystal structure that answered a question about LSD that had puzzled pharmacologists for decades.

Whether you want to understand what the lsd formula encodes, why the lsd structure produces effects at doses measured in millionths of a gram, or how lsd synthesis has been understood since Robert Woodward’s 1956 total synthesis of lysergic acid, everything is here.

▲ Left: The LSD molecule — tetracyclic ergoline scaffold (rings A–D), two stereocenters at C-5 and C-8 (only 5R,8R d-LSD is psychoactive), and diethylamide pharmacophore. Right: Claviceps purpurea ergot sclerotia on rye — the natural source of ergotamine and lysergic acid from which LSD is obtained. Sources: PubChem CID 5761; Wikipedia LSD; Passie et al. (2008).

What Is LSD? A Chemical Identity

The lsd formula is C₂₀H₂₅N₃O. Molecular weight: 323.43 g/mol. CAS number: 50-37-3. PubChem CID: 5761. IUPAC name: (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide. International Nonproprietary Name (INN): lysergide. These are not just registration data — each piece of that formula says something meaningful about how the molecule behaves.

LSD is classified as a semisynthetic compound, an ergoline alkaloid, and an indolalkylamine. As documented by ScienceDirect’s Contemporary Practice in Clinical Chemistry, it shares structural features with the neurotransmitter serotonin (5-hydroxytryptamine), which is the biochemical basis for its extraordinarily high binding affinity at the 5-HT2A serotonin receptor. Understanding the lsd chemical structure is not separate from understanding why LSD works — they are the same question.

✔ KEY FACT:  At an active dose of 100 micrograms, one gram of pure LSD contains approximately 10,000 individual doses. As Wikipedia documents, 25 kg of ergotamine tartrate precursor yields 5–6 kg of pure crystalline LSD — around 50–60 million doses. This mass-to-potency ratio, unmatched among psychoactive substances, is a direct consequence of the molecule’s precise three-dimensional fit to the 5-HT2A receptor.

The LSD Chemical Structure: Four Rings, One Pharmacophore

The lsd structure is built on a tetracyclic ergoline scaffold — four interconnected rings labeled A through D. This is the framework the ergot fungus biosynthesizes from tryptophan, and it is shared by the entire family of ergoline alkaloids, including pharmaceutical compounds like ergotamine, bromocriptine, and cabergoline. What makes LSD chemically distinct is the diethylamide group at C-8 on ring D — the component that gives the molecule its full name and its psychedelic pharmacophore.

The Four Rings and What Each Does

  • Ring A (benzene): Aromatic base of the indole system. Forms edge-to-face π-stacking contacts with phenylalanine residues (F340, F341) in the 5-HT2A receptor binding pocket, as revealed by the Wacker et al. (2017) crystal structure in Cell.
  • Ring B (pyrrole): Fused to ring A to form the indole bicyclic unit. The indole scaffold is also the core of serotonin and tryptamine — explaining LSD’s serotonin receptor affinity. Dipole moment: 3.04 D, almost identical to serotonin’s 2.98 D (University of Bristol, School of Chemistry).
  • Ring C (cyclohexene): Contains the C9=C10 double bond that locks the molecule into the three-dimensional shape required for receptor engagement.
  • Ring D (piperidine): Nitrogen-containing ring bearing the N-6 methyl group and — most importantly — the two chiral centers at C-5 and C-8. The diethylamide group at C-8 is the pharmacophore that makes LSD-25 distinct from simpler lysergamides.

Stereochemistry: The Geometry That Decides Everything

The lsd molecule has two stereocenters (C-5 and C-8) generating four possible stereoisomers. Only one is psychoactive: (+)-d-LSD with absolute configuration (5R,8R). The other three — iso-LSD (5R,8S), l-LSD (5S,8S), and l-iso-LSD — do not meaningfully bind the 5-HT2A receptor. As ScienceDirect documents, synthesizing pure d-LSD is technically demanding because LSD and iso-LSD rapidly interconvert in the presence of bases, since the C-8 alpha proton is acidic. Iso-LSD formed during synthesis is separated by chromatography and can be re-isomerized to active d-LSD under controlled acidic conditions.

One more structural fact that distinguishes the lsd molecule from virtually all other drugs: it is strongly fluorescent under UV light and pure LSD salts are triboluminescent, emitting small flashes of white light when shaken in the dark (Wikipedia). These properties — not pharmacological — are nevertheless forensically significant. The UV fluorescence (excitation 325 nm, emission 445 nm) is exploited in HPLC fluorescence detection and is one of the analytical signatures used in laboratory confirmation.

What Is LSD Made Of? The Biological Origin

LSD is obtained from ergot alkaloids produced by Claviceps purpurea — a parasitic fungus that infects rye (Secale cereale) and other cereal grains. Infected grain kernels are replaced by dark, hardened sclerotia dense with ergoline alkaloids: ergotamine, ergonovine, ergocristine, and related compounds. As the University of Bristol School of Chemistry documents, these alkaloids are biosynthesized by the fungus from the amino acid tryptophan via dimethylallyl diphosphate (DMAPP) — the same indole scaffold that connects LSD’s chemistry to serotonin.

What LSD is made from at its direct chemical level is two components. First, lysergic acid: obtained from alkaline hydrolysis of ergotamine tartrate, a Schedule III controlled substance used pharmaceutically for migraine treatment. Second, diethylamine: the simple secondary amine that provides the N,N-diethyl groups of the diethylamide pharmacophore. The lsd synthesis joins these two components through an amide coupling reaction — the same class of reaction that forms peptide bonds in protein chemistry, applied to a uniquely sensitive substrate.

⚠ LEGAL NOTE:  LSD is a Schedule I controlled substance in the United States and controlled under the 1971 UN Convention on Psychotropic Substances internationally. Synthesizing LSD without a DEA Schedule I researcher license is a federal felony. The synthesis chemistry described here is presented in educational terms consistent with Wikipedia, PubChem, and peer-reviewed literature. It is not synthesis guidance.

How Is LSD Made? The Synthesis Chemistry

The question of how lsd is made has a precise answer in the published scientific literature. LSD synthesis — lsd synthesis in its most general form — is an amide coupling reaction between activated lysergic acid and diethylamine. The challenge is the substrate: lysergic acid’s C-8 proton is acidic enough to be removed under basic conditions, causing isomerization to inactive iso-LSD. The C9=C10 double bond is susceptible to reduction. And the tertiary amine N-6 complicates activation conditions. Standard amide coupling agents that work fine for simple carboxylic acids often destroy the ergoline structure. This is why lsd synthesis requires advanced organic chemistry skill and equipment — not just knowledge of the reaction.

The Semisynthetic Route (Standard)

As Wikipedia documents, the standard production pathway begins with alkaline hydrolysis of ergotamine tartrate to yield lysergic acid, which is then activated — most commonly with phosphoryl chloride (POCl₃) or thionyl chloride (SOCl₂) — to form a reactive intermediate. Diethylamine is then added to complete the amide bond. After aqueous workup, the crude product contains both d-LSD and iso-LSD, which are separated by column chromatography. Iso-LSD can be re-isomerized to d-LSD under acidic conditions. Recrystallization yields pure crystalline d-LSD tartrate salt. The entire process from ergotamine to pure compound takes two to three days and produces 30 to 100 grams per batch (Wikipedia).

The Total Synthesis Route (Academic)

What is lsd made from in academic synthesis — without any ergot-derived starting material — was answered first by Robert B. Woodward’s team at Harvard in 1956. The Woodward synthesis was a 15-stage sequence beginning from β-carboxyethyl dihydroindole. As InnovationHub.world’s chemistry reference documents, Woodward used dihydroindole compounds as the base structure to overcome the highly reactive hetero ring system, converting to the indole of LSD in the final steps. A 2011 enantioselective synthesis by Fujii and Ohno (University of Osaka) used a palladium-catalyzed domino cyclization as the key ring-forming step. The most efficient published route to date is a six-step synthesis from Tuck, Dunlap, and Olson at UC Davis (Journal of Organic Chemistry, 2023), which was developed specifically to access LSD analogs for therapeutic research.

The frontier of LSD chemistry is no longer about how to make lsd but about what modifications to the lsd structure enable non-hallucinogenic therapeutic compounds. The 2025 PNAS paper by Dunlap and Olson at UC Davis demonstrated that transposing just two atoms in the LSD molecule creates JRT — a constitutional isomer with potent neuroplasticity-promoting effects but markedly reduced hallucinogenic potential at the 5-HT2A receptor. This is the direct scientific heir of Hofmann’s original work: systematic modification of the ergoline scaffold to find compounds that separate psychedelic from therapeutic effects.

▲ Left: The semisynthetic LSD production chain from ergotamine to pure d-LSD (CAS 50-37-3). Right: The 5-HT2A receptor–LSD crystal structure (Wacker et al., Cell 2017; Kim et al., Cell 2020), showing the EL2 extracellular loop forming a lid over the bound LSD molecule — the structural basis for LSD’s slow dissociation rate and 8–12-hour duration of effects despite a plasma half-life of ~3 hours.

How the LSD Structure Drives Its Unique Pharmacology

The most consequential piece of LSD science published in the past decade is the 2017 crystal structure of LSD bound to the human 5-HT2B serotonin receptor, published in Cell by Wacker, Wang, McCorvy, Betz, Venkatakrishnan, Levit, Roth, and colleagues at UNC Chapel Hill, Stanford, and UCSF (PMID: 28041749). The structure answered a question that had puzzled pharmacologists for years: why does LSD produce effects lasting 8 to 12 hours when its plasma half-life is only approximately 3 hours?

The answer is structural. The ergoline core of the lsd molecule is anchored in the receptor’s orthosteric binding pocket by a conserved salt bridge between the ring nitrogen and aspartate D135 in transmembrane helix III. But the critical finding was that extracellular loop 2 (EL2) of the receptor physically closes over the bound LSD molecule like a lid — preventing it from dissociating quickly. When Wacker et al. introduced a mutation to destabilize this lid, LSD’s dissociation rate increased approximately 10-fold. The lid is not a passive structural feature. It actively determines how long LSD remains receptor-bound, and therefore how long its effects persist.

A follow-up crystal structure of LSD bound directly to 5-HT2A (its primary target) was published in Cell in 2020 by Kim, Che, Wacker, Roth, and colleagues at UNC and Stanford (PMID: 32846101). The 5-HT2A structure identified residue S242 in helix V as unique to 5-HT2A compared to 5-HT2B, and showed that this difference extends LSD’s receptor residence time further still. Together, these two structures provide the most complete molecular account of how the lsd chemical structure determines the compound’s pharmacological fingerprint.

CLINICAL INSIGHT:  The EL2 receptor lid mechanism (Wacker et al. 2017) explains a clinical reality: once LSD has bound to 5-HT2A receptors, no pharmacological intervention meaningfully shortens the experience. Benzodiazepines like diazepam can reduce acute anxiety by activating GABA-A receptors, but they cannot displace LSD from 5-HT2A or affect the lid. The experience runs its course independent of plasma concentration — a direct consequence of the lsd structure’s interaction with its receptor.

Two Sub-Topics Covered in Dedicated Articles

This article provides the chemistry and science overview. Each of the following receives a full, standalone deep dive in its own article:

  • Chemical Structure & Formula — Complete atomic-resolution detail on the lsd chemical structure: stereochemistry analysis at C-5 and C-8, spectroscopic data (¹H NMR shifts, UV absorption maxima at 254 nm and 313 nm, MS fragmentation pattern), dipole moment comparison with serotonin, the Wacker et al. (2017) and Kim et al. (2020) receptor crystal structure findings in full, physical properties (fluorescence, triboluminescence, stability), and how the lsd formula maps to 5-HT2A binding geometry. Also covers the LSD analog family: 1P-LSD, ALD-52, BOL-148, ETH-LAD, LSA, and JRT (PNAS 2025).
  • Origins & Synthesis — The complete account of where LSD comes from and how it has been made: Hofmann’s original 1938 Sandoz synthesis step by step (the Curtius method), the 1956 Woodward total synthesis of lysergic acid, modern academic routes including the Fujii/Ohno enantioselective palladium synthesis (2011) and the Tuck/Dunlap/Olson six-step route (J. Org. Chem. 2023), the biosynthetic pathway in Claviceps purpurea from tryptophan through ergotamine, and the full precursor regulatory framework (DEA schedules, UN Convention Table I and II).

Conclusion: Actionable Takeaways

  • The lsd formula is C₂₀H₂₅N₃O — MW 323.43 g/mol, CAS 50-37-3, PubChem CID 5761. One gram contains approximately 10,000 doses at 100 mcg. The mass-to-potency ratio is unmatched among psychoactive compounds.
  • The lsd chemical structure is a tetracyclic ergoline scaffold (rings A–D), with a diethylamide pharmacophore at C-8. Only the (5R,8R) d-LSD stereoisomer is psychoactive. The near-identical dipole moment to serotonin (3.04 vs 2.98 D) explains its 5-HT2A receptor affinity.
  • LSD is obtained from Claviceps purpurea ergot alkaloids. What LSD is made from chemically: lysergic acid (from ergotamine hydrolysis) + diethylamine, joined via amide coupling with phosphoryl chloride or thionyl chloride as activating agent.
  • The lsd structure’s 8–12-hour duration is not explained by its plasma half-life (~3 hours) but by the EL2 receptor lid (Wacker et al., Cell 2017) that physically traps LSD in the 5-HT2A binding pocket. This is the most pharmacologically consequential structural insight about any psychedelic compound to date.
  • How to make lsd academically — total synthesis — has been achieved in as few as six steps (Tuck et al., J. Org. Chem. 2023), though all synthesis requires DEA Schedule I authorization. The frontier is now analog synthesis: the PNAS 2025 paper by Dunlap and Olson (UC Davis) shows that transposing two atoms creates JRT, a non-hallucinogenic neuroplastogen derived from LSD’s structure.
  • For harm reduction: field identification uses the Ehrlich reagent (purple = indole alkaloid). Lab confirmation uses chiral HPLC or LC-MS/MS to verify d-LSD identity and purity. UV fluorescence at 325/445 nm is an additional confirmatory property unique to the intact LSD molecule.

About the Author

👤  Dr. Sarah Chen, PharmD, PhD Clinical Pharmacologist — University of California, San Francisco  |  Johns Hopkins University (PhD Pharmacology)  Dr. Sarah Chen holds a Doctor of Pharmacy from UCSF and a PhD in Pharmacology from Johns Hopkins University, with specialization in serotonergic receptor pharmacology and ergoline alkaloid chemistry. Her published work covers structure–activity relationships of 5-HT2A ligands and their clinical implications for psychedelic-assisted therapy research. She draws exclusively from primary peer-reviewed sources and registered chemical databases. No financial relationships with companies developing psychedelic therapies.

References

1. Hofmann, A. (2005). Notes and documents concerning the discovery of LSD. Agents and Actions, 43(1–2), 79–81. https://doi.org/10.1007/BF01986673

2. Passie, T., Halpern, J.H., Stichtenoth, D.O., Emrich, H.M., & Hintzen, A. (2008). The pharmacology of LSD: A review. CNS Neuroscience & Therapeutics, 14(4), 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x

3. Wacker, D., Wang, S., McCorvy, J.D., Betz, R.M., Venkatakrishnan, A.J., Levit, A., … Roth, B.L. (2017). Crystal structure of an LSD-bound human serotonin receptor. Cell, 168(3), 377–389.e12. https://doi.org/10.1016/j.cell.2016.12.033. PMID: 28041749.

4. Kim, K., Che, T., Panova, O., DiBerto, J.F., Lyu, J., Krumm, B.E., … Roth, B.L. (2020). Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell, 182(6), 1574–1588.e19. https://doi.org/10.1016/j.cell.2020.08.024. PMID: 32846101.

5. Nichols, D.E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478

6. Tuck, J.R., Dunlap, L.E., & Olson, D.E. (2023). Synthetic strategies toward LSD: Ergoline synthesis via α-arylation, borrowing hydrogen alkylation, and C–H insertion. Journal of Organic Chemistry, 88(19), 13712–13719. https://doi.org/10.1021/acs.joc.3c01363

7. Dunlap, L.E., & Olson, D.E. (2025). Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential. Proceedings of the National Academy of Sciences, 122(16), e2416106122. https://doi.org/10.1073/pnas.2416106122

8. Schiff, P.L. (2006). Ergot and its alkaloids. American Journal of Pharmaceutical Education, 70(5), 98. https://pmc.ncbi.nlm.nih.gov/articles/PMC1637017/

9. Dolder, P.C., Schmid, Y., Steuer, A.E., Kraemer, T., Rentsch, K.M., Hammann, F., & Liechti, M.E. (2017). Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clinical Pharmacokinetics, 56(10), 1219–1230. https://doi.org/10.1007/s40262-016-0479-3

10. Gartz, J., et al. (2022). Methods of lysergic acid synthesis — the key ergot alkaloid. International Journal of Molecular Sciences. PMC9654825.

11. PubChem. (+)-Lysergic acid diethylamide. CID 5761. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/5761

12. May, P. (1998). LSD — Molecule of the Month. University of Bristol School of Chemistry. https://www.chm.bris.ac.uk/motm/lsd/lsd1_text.htm

13. Wikipedia. (2026). Lysergic acid diethylamide. https://en.wikipedia.org/wiki/LSD

14. ScienceDirect. Lysergic acid diethylamide. Contemporary Practice in Clinical Chemistry (4th ed., 2020). Langman, L.J. & Jannetto, P.J. https://www.sciencedirect.com/topics/medicine-and-dentistry/lysergic-acid-diethylamide